---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-25-000009"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T06:48:20.758893+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad discloses Sartorius AG FY2024 results: revenue €3.38B, net profit €137.4M

## Summary
- Sartorius AG reported FY2024 sales revenue of €3,380.7M, gross profit €1,524.4M, EBIT €392.6M.
- Net profit for FY2024 was €137.4M; operating cash flow €976.2M, investing cash flow -€425.8M.
- As of Dec 31, 2024, Sartorius had total assets €10,103.0M, total liabilities €6,205.2M, equity €3,897.8M.
- Bio-Rad does not assume responsibility for Sartorius's publicly disclosed figures; refers to Sartorius's annual report.
- Update relates to Bio-Rad's Investment in Sartorius AG section of its 2024 10-K filed Feb 14, 2025.

## SEC filing metadata
- accession: 0000012208-25-000009
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220825000009/0000012208-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220825000009/bio-20250221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-25-000009
- JSON: https://secwatch.observer/filing/0000012208-25-000009.json
- Plain text: https://secwatch.observer/filing/0000012208-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.